Evidence map›Paper›PMID 35822118›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2022

General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.

Toshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Koji Joko, Takehiro Akahane, Koichiro Furuta and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 14 institutions in 1 country.

Toshifumi TadaDepartment of Internal Medicine Japanese Red Cross Society Himeji Hospital Himeji Japan.ORCID https://orcid.org/0000-0002-0976-6761
Masayuki KurosakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Nobuharu TamakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Yutaka YasuiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Nami MoriDepartment of Gastroenterology Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital Hiroshima Japan.
Keiji TsujiDepartment of Gastroenterology Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital Hiroshima Japan.
Chitomi HasebeDepartment of Gastroenterology Japanese Red Cross Asahikawa Hospital Asahikawa Japan.
Koji JokoCenter for Liver-Biliary-Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan.
Takehiro AkahaneDepartment of Gastroenterology Japanese Red Cross Ishinomaki Hospital Ishinomaki Japan.
Koichiro FurutaDepartment of Gastroenterology Masuda Red Cross Hospital Masuda Japan.
Haruhiko KobashiDepartment of Gastroenterology Japanese Red Cross Okayama Hospital Okayama Japan.
Hideki FujiiDepartment of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
Toru IshiiDepartment of Gastroenterology Japanese Red Cross Akita Hospital Akita Japan.
Hiroyuki MarusawaDepartment of Gastroenterology and Hepatology Japanese Red Cross Osaka Hospital Osaka Japan.
Masahiko KondoDepartment of Gastroenterology Japanese Red Cross Otsu Hospital Otsu Shiga Japan.
Yuji KojimaDepartment of Hepatology Japanese Red Cross Ise Hospital Ise Japan.
Hideo YoshidaDepartment of Gastroenterology Japanese Red Cross Medical Center Tokyo Japan.
Yasushi UchidaDepartment of Gastroenterology Japanese Red Cross Matsue Hospital Matsue Japan.
Shinichiro NakamuraDepartment of Internal Medicine Japanese Red Cross Society Himeji Hospital Himeji Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Musashino Red Cross Hospital · JPHimeji Red Cross Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPAkita Red Cross Hospital · JPIse Red Cross Hospital · JPJapanese Red Cross Asahikawa Hospital · JPJapanese Red Cross Medical Center · JPKyoto first Red Cross hospital · JPMatsue Red Cross Hospital · JPMatsuyama Red Cross Hospital · JPOkayama Red Cross General Hospital · JPOsaka Hospital · JPOtsu Red Cross Hospital · JPTsuda University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: To validate a composite predictive model for hepatocellular carcinoma (HCC) development in patients with advanced liver fibrosis associated with chronic hepatitis C virus (HCV) who have received direct-acting antiviral (DAA) therapy and achieved sustained virologic response (SVR). Methods: This study included 1258 patients with advanced liver fibrosis associated with HCV genotype 1, 2, or both. General evaluation score (GES), which is based on sex, age, fibrosis stage, albumin, and α-fetoprotein, was used as a composite predictive model. Results: There were 645 (51.3%) patients in the low-risk group, 228 (18.1%) in the intermediate-risk group, and 385 (30.6%) in the high-risk group based on GES categories. The 12-, 36-, and 60-month cumulative incidence of HCC was 0.7%, 5.3%, and 13.0%, respectively. Multivariable analysis with Cox proportional hazards models showed that male sex (hazard ratio [HR], 1.863; 95% confidence interval [CI], 1.204-2.883), F4 fibrosis stage (HR, 3.199; 95% CI, 1.696-6.036), and albumin (HR, 0.489; 95% CI, 0.288-0.828) are independently associated with HCC development. The incidence of HCC differed significantly by GES-based risk category ( Conclusion: GES is useful for predicting HCC development in patients with advanced liver fibrosis after SVR.

Indexed as

advanced liver fibrosisdirect‐acting antiviralgeneral evaluation scorehepatitis C virushepatocellular carcinomasustained virologic response

Identifiers

PMID35822118
PMCPMC9260214
OpenAlexW4281931488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.